Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2004, Vol. 15 ›› Issue (1): 39

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Preparation and bio-distribution of bone tumor therapeutic agent 188Re-TCTMP

JIANG Shu-Bin,1 LUO Shun-Zhong,1 DENG Hou-Fu,2 BIN Wen-Zeng,1 WANG Wen-Jin,1 WEI Hong-Yuan,1 LIU Guo-Ping1   

  1. 1Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900;
    2Department of Nuclear Medicine of First University Hospital, West China Medicine Center, Sichuan University, Chengdu 610041
PDF ShareIt Export Citation
JIANG Shu-Bin, LUO Shun-Zhong, DENG Hou-Fu, BIN Wen-Zeng, WANG Wen-Jin, WEI Hong-Yuan, LIU Guo-Ping. Preparation and bio-distribution of bone tumor therapeutic agent 188Re-TCTMP.Nuclear Science and Techniques, 2004, 15(1): 39

Abstract: TCTMP (1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonate) was synthesized and coupled with 188Re. The 188Re-TCTMP’s coupling condition, stability and bio-distribution in mice were investigated. The results showed that satisfactory yield of 188Re could be obtained under the conditions of media pH=2.0, 0.8~1.6 mg of SnCl2 and 50 mg of ligand. 188Re-TCTMP was stable (complexation yield >95%) in 8 d without protection of N2. The result of bio-distribution indicated that 188Re-TCTMP had a strong affinity to skeleton and very low non-target tissue’s uptake, and the amount of 188Re-TCTMP in blood was (0.06±0.02)%ID/g 6 h after injection, whereas the concentration of 188Re-HEDP (1-hydroxy-ethylidene diphosphonate) in blood was (0.28±0.05)%ID/g 6 h after injection. Compared with 188Re-HEDP, 188Re-TCTMP exhibits better potential for the treatment of metastases.

Key words: 188Re, TCTMP, Bone tumor, Bio-distribution